All In Biotech

Drug Trial Radar · NCT00724126

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 637 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

637

Actual

Start

Jul 2008

Primary completion

Aug 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jul 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.

Conditions

  • Non-Constipation Irritable Bowel Syndrome

Interventions

  • RifaximinDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).Time frame: 4 weeks

Locations

88 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Anniston, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Tempe, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Carmichael, California

  • Site not named

    Chula Vista, California

  • Site not named

    Concord, California

  • Site not named

    Garden Grove, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Lakewood, California

  • Site not named

    Los Angeles, California

  • Site not named

    Monterey, California

  • Site not named

    Orange, California

  • Site not named

    Roseville, California

  • Site not named

    San Carlos, California

  • Site not named

    San Francisco, California

  • Site not named

    Bristol, Connecticut

  • Site not named

    Hamden, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Boca Raton, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Largo, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    New Smyrna Beach, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Elkhart, Indiana

  • Site not named

    Kansas City, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Bowling Green, Kentucky

  • Site not named

    Metairie, Louisiana

  • Site not named

    Monroe, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Elkridge, Maryland

  • Site not named

    Wellesley, Massachusetts

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.